
## Batia Kaplan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7892641/publications.pdf Version: 2024-02-01



<u> ΒΑΤΙΑ ΚΑΒΙΑΝ</u>

#	Article	IF	CITATIONS
1	Immunoglobulin Free Light Chain Dimers in Human Diseases. Scientific World Journal, The, 2011, 11, 726-735.	0.8	58
2	Biochemical Subtyping of Amyloid in Formalin-Fixed Tissue Samples Confirms and Supplements Immunohistologic Data. American Journal of Clinical Pathology, 2004, 121, 794-800.	0.4	57
3	P-053. The role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction, 1999, 14, 167-167.	0.4	53
4	[5] Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. Methods in Enzymology, 1999, 309, 67-81.	0.4	52
5	Free light chain monomers in the diagnosis of multiple sclerosis. Journal of Neuroimmunology, 2010, 229, 263-271.	1.1	52
6	α-Synuclein: Its Biological Function and Role in Neurodegenerative Diseases. Journal of Molecular Neuroscience, 2003, 20, 83-92.	1.1	50
7	Free light chains in plasma of patients with light chain amyloidosis and nonâ€amyloid light chain deposition disease. High proportion and heterogeneity of disulfideâ€linked monoclonal free light chains as pathogenic features of amyloid disease. British Journal of Haematology, 2009, 144, 705-715.	1.2	35
8	Amino-terminal identity of co-existent amyloid and non-amyloid immunoglobulin κ light chain deposits. A human disease to study alterations of protein conformation. Clinical and Experimental Immunology, 1997, 110, 472-478.	1.1	33
9	Effect of Perilesional Injections of PEG-Interleukin-2 on Basal Cell Carcinoma. Dermatologic Surgery, 2000, 26, 1037-1040.	0.4	33
10	pH-dependent fibrillogenesis of a VκIII Bence Jones protein. British Journal of Haematology, 1999, 107, 835-843.	1.2	31
11	Micro-method to isolate and purify amyloid proteins for chemical characterization. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 22-29.	1.4	31
12	TREATMENT OF PYODERMA GANGRENOSUM WITH CLOFAZIMINE. International Journal of Dermatology, 1992, 31, 591-593.	0.5	30
13	Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. British Journal of Haematology, 2007, 136, 723-728.	1.2	30
14	Co-deposition of amyloidogenic immunoglobulin light and heavy chains in localized pulmonary amyloidosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 756-761.	1.4	28
15	Micropurification techniques in the analysis of amyloid proteins. Journal of Clinical Pathology, 2003, 56, 86-90.	1.0	26
16	Free light chain monomer–dimer patterns in the diagnosis of multiple sclerosis. Journal of Immunological Methods, 2013, 390, 74-80.	0.6	26
17	Isolation and Characterization of Amyloid Proteins Using Milligram Amounts of Amyloid - Containing Tissue. Journal of Liquid Chromatography and Related Technologies, 1993, 16, 2249-2268.	0.9	25
18	Search for peptidic "middle molecules―in uremic sera: isolation and chemical identification of fibrinogen fragments. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 141-153.	1.2	25

Batia Kaplan

#	Article	IF	CITATIONS
19	Comparison of Room Temperature and Warmed Local Anesthetic Solution for Tumescent Liposuction. Dermatologic Surgery, 1996, 22, 707-709.	0.4	24
20	Immunochemical characterization of amyloid in diagnostic biopsy tissues. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 80-86.	1.4	24
21	lmmunoglobulinâ€free light chain monomerâ€dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: A pilot study. American Journal of Hematology, 2014, 89, 882-888.	2.0	23
22	Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clinical Chemistry and Laboratory Medicine, 2008, 46, 335-41.	1.4	22
23	Biochemical Subtyping of Amyloid in Formalin-Fixed Tissue Samples Confirms and Supplements Immunohistologic Data. American Journal of Clinical Pathology, 2004, 121, 794-800.	0.4	20
24	The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. British Journal of Haematology, 2018, 182, 86-92.	1.2	17
25	ltraconazole versus ketoconazole in the treatment of tinea versicolor. Journal of Dermatological Treatment, 1999, 10, 19-23.	1.1	16
26	lmmunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis. Clinical and Experimental Immunology, 2018, 192, 7-17.	1.1	10
27	Diagnostic utility of kappa free light chains in multiple sclerosis. Expert Review of Molecular Diagnostics, 2019, 19, 277-279.	1.5	10
28	Separation of proteins by consecutive sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and reversed phase high performance liquid chromatography. Biomedical Chromatography, 1991, 5, 86-89.	0.8	8
29	Primary local orbital amyloidosis: biochemical identification of the immunoglobulin light chain ÂIII subtype in a small formalin fixed, paraffin wax embedded tissue sample. Journal of Clinical Pathology, 2005, 58, 539-542.	1.0	8
30	Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102339.	0.9	8
31	Removal of sodium dodecyl sulphate from proteins isolated by sodium dodecyl sulphate polyacrylamide gel electrophoresis. Biomedical Chromatography, 1990, 4, 89-90.	0.8	7
32	Open randomized comparison of different itraconazole regimens for the treatment of onychomycosis. Journal of Dermatological Treatment, 1999, 10, 245-249.	1.1	7
33	Gastrointestinal β2microglobulin amyloidosis in hemodialysis patients: biochemical analysis of amyloid proteins in small formalin-fixed paraffin-embedded tissue specimens. Modern Pathology, 2005, 18, 1610-1617.	2.9	7
34	Separation of Amyloid Proteins by Size-Exclusion Chromatography in Aqueous Organic Mobile Phase. Journal of Liquid Chromatography and Related Technologies, 1992, 15, 2467-2486.	0.9	6
35	Search for new biomarkers of pediatric multiple sclerosis: application of immunoglobulin free light chain analysis. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1081-1089.	1.4	6
36	Biochemical Micro-Techniques in the Diagnosis and Classification of Amyloidosis. Current Pharmaceutical Analysis, 2006, 2, 45-52.	0.3	5

Batia Kaplan

#	Article	IF	CITATIONS
37	Quantification of tissue amyloid content in AA amyloidosis by inhibition ELISA. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 167-172.	1.4	4
38	Combined use of micro-preparative gel electrophoresis and reversed-phase high-performance liquid chromatography for purification of amyloid β peptides deposited in brains of Alzheimer's disease patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 769, 363-370.	1.2	4
39	FLC polymerization: Another hurdle towards standardization of FLC measurements. Clinica Chimica Acta, 2021, 515, 42-43.	0.5	4
40	Self-health attitudes and practices of obstetrics and gynecology nurses in Israel. Clinical and Experimental Obstetrics and Gynecology, 2002, 29, 115-6.	0.1	4
41	Transthyretin amyloidosis in a patient of Iranian-Jewish extraction: a second Israeli-Jewish case. Clinical Chemistry and Laboratory Medicine, 2007, 45, 625-8.	1.4	3
42	Interleukin 1beta in serum of women with preterm uterine contractions. Journal of Obstetrics and Gynaecology, 1997, 17, 444-445.	0.4	2
43	The health-promoting behaviors and attitude towards menopause and hormone replacement therapy among women on dialysis. Gynecological Endocrinology, 2002, 16, 349-354.	0.7	2
44	Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis. Clinical and Experimental Nephrology, 2019, 23, 763-772.	0.7	2
45	Personalized Disease Monitoring in Pediatric Onset Multiple Sclerosis Using the Saliva Free Light Chain Test. Frontiers in Immunology, 2022, 13, 821499.	2.2	2
46	Knowledge and attitude towards personal health care and menopause among women with ischemic heart disease undergoing coronary angiography. Gynecological Endocrinology, 2003, 17, 255-259.	0.7	1
47	Successful external version of B-twin after the birth of A-twin for vertexnon-vertex twins. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1995, 58, 157-60.	0.5	1
48	Cytopathological and bacteriological findings in women using intrauterine contraceptive devices. Journal of Obstetrics and Gynaecology, 1996, 16, 188-191.	0.4	0
49	Selective second trimester fetal reduction due to 46XY, 10q+ fetus. Clinical and Experimental Obstetrics and Gynecology, 1996, 23, 141-3.	0.1	0
50	Multiple Myeloma with Systemic Amyloidosis: Serum Free Light Chain Dimerization Analysis in the Diagnosis of an Equivocal Case of Plasma Cell Dyscrasia. Israel Medical Association Journal, 2021, 23, 459-461.	0.1	0
51	The health-promoting behaviors and attitude towards menopause and hormone replacement therapy among women on dialysis. Gynecological Endocrinology, 2002, 16, 349-354.	0.7	0
52	Knowledge and attitude towards personal health care and menopause among women with ischemic heart disease undergoing coronary angiography. Gynecological Endocrinology, 2003, 17, 255-259.	0.7	0
53	Induction of labor with vaginal prostaglandin E2. Journal of Maternal-Fetal and Neonatal Medicine, 2003, 14, 30-34.	0.7	0